questionsmedicales.fr
Technologie, industrie et agriculture
Industrie
Secteur secondaire
Industrie pharmaceutique
Industrie pharmaceutique : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Essais cliniques
Efficacité des médicaments
Essais cliniques
Phase III
Critères d'inclusion
Essais cliniques
Effets secondaires
Pharmacovigilance
Symptômes
5
Réaction médicamenteuse
Effets indésirables
Allergie médicamenteuse
Réactions allergiques
Overdose
Intoxication médicamenteuse
Interaction médicamenteuse
Effets indésirables
Effets secondaires
Pharmacovigilance
Prévention
5
Effets indésirables
Pharmacovigilance
Prescription médicale
Pratiques cliniques
Sensibilisation
Éducation à la santé
Interactions médicamenteuses
Conseils médicaux
Polymédication
Gestion des médicaments
Traitements
5
Développement de médicaments
Essais cliniques
Médicaments génériques
Pharmacie
Thérapie ciblée
Oncologie
Médicaments orphelins
Maladies rares
Mise sur le marché
Réglementation des médicaments
Complications
5
Complications médicamenteuses
Effets indésirables
Réaction allergique
Urgences médicales
Surdosage
Intoxication médicamenteuse
Médicaments anticancéreux
Effets indésirables
Facteurs de risque
5
Facteurs de risque
Effets indésirables
Alcool
Interactions médicamenteuses
Médicaments à risque
Personnes âgées
Maladies chroniques
Pharmacologie
Automédication
Risques médicaux
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Industrie pharmaceutique : Questions médicales les plus fréquentes",
"headline": "Industrie pharmaceutique : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Industrie pharmaceutique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-13",
"dateModified": "2025-04-07",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Industrie pharmaceutique"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Secteur secondaire",
"url": "https://questionsmedicales.fr/mesh/D066192",
"about": {
"@type": "MedicalCondition",
"name": "Secteur secondaire",
"code": {
"@type": "MedicalCode",
"code": "D066192",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "J01.576.655"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Médicament orphelin",
"alternateName": "Orphan Drug Production",
"url": "https://questionsmedicales.fr/mesh/D009965",
"about": {
"@type": "MedicalCondition",
"name": "Médicament orphelin",
"code": {
"@type": "MedicalCode",
"code": "D009965",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "J01.576.655.750.600"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Industrie pharmaceutique",
"alternateName": "Drug Industry",
"code": {
"@type": "MedicalCode",
"code": "D004345",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Beatriz G de la Torre",
"url": "https://questionsmedicales.fr/author/Beatriz%20G%20de%20la%20Torre",
"affiliation": {
"@type": "Organization",
"name": "KRISP, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa."
}
},
{
"@type": "Person",
"name": "Fernando Albericio",
"url": "https://questionsmedicales.fr/author/Fernando%20Albericio",
"affiliation": {
"@type": "Organization",
"name": "School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa."
}
},
{
"@type": "Person",
"name": "Christophe Tistaert",
"url": "https://questionsmedicales.fr/author/Christophe%20Tistaert",
"affiliation": {
"@type": "Organization",
"name": "Small Molecules Pharmaceutical Development, Drug Product Development, Biopharmaceutics, Janssen Research and Development, Beerse, Belgium."
}
},
{
"@type": "Person",
"name": "Tycho Heimbach",
"url": "https://questionsmedicales.fr/author/Tycho%20Heimbach",
"affiliation": {
"@type": "Organization",
"name": "Department of PK Sciences, PBPK and Biopharmaceutics Section, Novartis Institutes for BioMedical Research, East Hanover, New Jersey 07936."
}
},
{
"@type": "Person",
"name": "Joel Lexchin",
"url": "https://questionsmedicales.fr/author/Joel%20Lexchin",
"affiliation": {
"@type": "Organization",
"name": "School of Health Policy and Management, York University, Toronto, ON, Canada."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "[The virtual ILD board: a pilot project].",
"datePublished": "2023-09-11",
"url": "https://questionsmedicales.fr/article/37696286",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1055/a-2113-0556"
}
},
{
"@type": "ScholarlyArticle",
"name": "A realist review of dyslexia pilot project research.",
"datePublished": "2023-06-10",
"url": "https://questionsmedicales.fr/article/37300716",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11881-023-00284-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "A Quality Improvement Pilot Project for Noise Reduction in the NICU.",
"datePublished": "2023-04-05",
"url": "https://questionsmedicales.fr/article/37018178",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/ANC.0000000000001074"
}
},
{
"@type": "ScholarlyArticle",
"name": "Suicide Attempt Aftercare in Geriatric Patients: A Pilot Project.",
"datePublished": "2022-09-28",
"url": "https://questionsmedicales.fr/article/36170052",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/01612840.2022.2127039"
}
},
{
"@type": "ScholarlyArticle",
"name": "Diagnostic Adjunct Techniques in the Assessment of Hypovolemia: A Prospective Pilot Project.",
"datePublished": "2023-09-10",
"url": "https://questionsmedicales.fr/article/37690381",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jss.2023.08.005"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Technologie, industrie et agriculture",
"item": "https://questionsmedicales.fr/mesh/D013676"
},
{
"@type": "ListItem",
"position": 3,
"name": "Industrie",
"item": "https://questionsmedicales.fr/mesh/D007221"
},
{
"@type": "ListItem",
"position": 4,
"name": "Secteur secondaire",
"item": "https://questionsmedicales.fr/mesh/D066192"
},
{
"@type": "ListItem",
"position": 5,
"name": "Industrie pharmaceutique",
"item": "https://questionsmedicales.fr/mesh/D004345"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Industrie pharmaceutique - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Industrie pharmaceutique",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-08",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Industrie pharmaceutique",
"description": "Comment évaluer l'efficacité d'un médicament ?\nQu'est-ce qu'une étude de phase III ?\nQuels sont les critères d'inclusion dans un essai ?\nComment sont mesurés les effets secondaires ?\nQu'est-ce qu'un placebo ?",
"url": "https://questionsmedicales.fr/mesh/D004345?mesh_terms=Pilot+Projects#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Industrie pharmaceutique",
"description": "Quels symptômes peuvent indiquer une réaction médicamenteuse ?\nComment reconnaître une allergie médicamenteuse ?\nQuels signes d'overdose sont fréquents ?\nQuels symptômes d'une interaction médicamenteuse ?\nComment identifier un effet secondaire rare ?",
"url": "https://questionsmedicales.fr/mesh/D004345?mesh_terms=Pilot+Projects#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Industrie pharmaceutique",
"description": "Comment prévenir les effets indésirables des médicaments ?\nQuelles sont les bonnes pratiques de prescription ?\nComment sensibiliser aux risques médicamenteux ?\nQuels conseils pour éviter les interactions médicamenteuses ?\nComment gérer les prescriptions multiples ?",
"url": "https://questionsmedicales.fr/mesh/D004345?mesh_terms=Pilot+Projects#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Industrie pharmaceutique",
"description": "Comment sont développés les nouveaux médicaments ?\nQu'est-ce qu'un médicament générique ?\nComment fonctionne la thérapie ciblée ?\nQu'est-ce qu'un médicament orphelin ?\nComment se déroule la mise sur le marché d'un médicament ?",
"url": "https://questionsmedicales.fr/mesh/D004345?mesh_terms=Pilot+Projects#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Industrie pharmaceutique",
"description": "Quelles complications peuvent survenir avec les médicaments ?\nComment gérer une réaction allergique grave ?\nQuels sont les risques de surdosage ?\nComment prévenir les complications liées aux traitements ?\nQuelles sont les complications des médicaments anticancéreux ?",
"url": "https://questionsmedicales.fr/mesh/D004345?mesh_terms=Pilot+Projects#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Industrie pharmaceutique",
"description": "Quels facteurs augmentent le risque d'effets secondaires ?\nComment l'alcool influence-t-il les médicaments ?\nQuels médicaments sont à risque pour les personnes âgées ?\nComment les maladies chroniques affectent-elles la médication ?\nQuels sont les risques liés à l'automédication ?",
"url": "https://questionsmedicales.fr/mesh/D004345?mesh_terms=Pilot+Projects#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment évaluer l'efficacité d'un médicament ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par des essais cliniques et des études de marché."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'une étude de phase III ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est une étude qui teste l'efficacité d'un médicament sur un grand nombre de patients."
}
},
{
"@type": "Question",
"name": "Quels sont les critères d'inclusion dans un essai ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères d'inclusion définissent les caractéristiques des participants éligibles."
}
},
{
"@type": "Question",
"name": "Comment sont mesurés les effets secondaires ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires sont mesurés par des rapports de patients et des études post-commercialisation."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'un placebo ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un placebo est un traitement inactif utilisé comme référence dans les essais cliniques."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer une réaction médicamenteuse ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des éruptions cutanées, des nausées ou des vertiges peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une allergie médicamenteuse ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les allergies se manifestent par des démangeaisons, des rougeurs ou un gonflement."
}
},
{
"@type": "Question",
"name": "Quels signes d'overdose sont fréquents ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent confusion, somnolence, et troubles respiratoires."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'une interaction médicamenteuse ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des vertiges, des palpitations ou des troubles digestifs peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Comment identifier un effet secondaire rare ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires rares sont souvent identifiés par des études de pharmacovigilance."
}
},
{
"@type": "Question",
"name": "Comment prévenir les effets indésirables des médicaments ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par une prescription appropriée et une surveillance des patients."
}
},
{
"@type": "Question",
"name": "Quelles sont les bonnes pratiques de prescription ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les bonnes pratiques incluent l'évaluation des antécédents médicaux et la communication avec le patient."
}
},
{
"@type": "Question",
"name": "Comment sensibiliser aux risques médicamenteux ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "La sensibilisation se fait par des campagnes d'information et des formations pour les professionnels."
}
},
{
"@type": "Question",
"name": "Quels conseils pour éviter les interactions médicamenteuses ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est conseillé de toujours informer le médecin de tous les médicaments pris, y compris les OTC."
}
},
{
"@type": "Question",
"name": "Comment gérer les prescriptions multiples ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique une coordination entre les différents prescripteurs et un suivi régulier."
}
},
{
"@type": "Question",
"name": "Comment sont développés les nouveaux médicaments ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les nouveaux médicaments sont développés par la recherche, les essais cliniques et l'approbation réglementaire."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'un médicament générique ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un médicament générique est une version d'un médicament de marque, généralement moins coûteuse."
}
},
{
"@type": "Question",
"name": "Comment fonctionne la thérapie ciblée ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie ciblée agit sur des molécules spécifiques impliquées dans la maladie."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'un médicament orphelin ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un médicament orphelin est destiné à traiter des maladies rares, souvent sans alternatives."
}
},
{
"@type": "Question",
"name": "Comment se déroule la mise sur le marché d'un médicament ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La mise sur le marché nécessite des essais cliniques, une évaluation réglementaire et une approbation."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les médicaments ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des réactions allergiques, des surdosages et des interactions."
}
},
{
"@type": "Question",
"name": "Comment gérer une réaction allergique grave ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une réaction allergique grave nécessite une intervention médicale immédiate, comme l'adrénaline."
}
},
{
"@type": "Question",
"name": "Quels sont les risques de surdosage ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le surdosage peut entraîner des dommages organiques, des troubles neurologiques ou la mort."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications liées aux traitements ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par un suivi régulier et une évaluation des effets secondaires."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications des médicaments anticancéreux ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des infections, des nausées et des troubles sanguins."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'effets secondaires ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge, le poids, les maladies préexistantes et les interactions médicamenteuses augmentent le risque."
}
},
{
"@type": "Question",
"name": "Comment l'alcool influence-t-il les médicaments ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'alcool peut intensifier les effets des médicaments, augmentant le risque d'effets indésirables."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont à risque pour les personnes âgées ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les médicaments à risque incluent les sédatifs, les anticoagulants et certains analgésiques."
}
},
{
"@type": "Question",
"name": "Comment les maladies chroniques affectent-elles la médication ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les maladies chroniques peuvent modifier la réponse aux médicaments et augmenter les effets secondaires."
}
},
{
"@type": "Question",
"name": "Quels sont les risques liés à l'automédication ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'automédication peut entraîner des interactions, des surdosages et des retards de traitement."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 07/04/2025
Contenu vérifié selon les dernières recommandations médicales
6 publications dans cette catégorie
Affiliations :
KRISP, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa.
6 publications dans cette catégorie
Affiliations :
School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa.
CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine, Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain.
3 publications dans cette catégorie
Affiliations :
Small Molecules Pharmaceutical Development, Drug Product Development, Biopharmaceutics, Janssen Research and Development, Beerse, Belgium.
Publications dans "Industrie pharmaceutique" :
3 publications dans cette catégorie
Affiliations :
Department of PK Sciences, PBPK and Biopharmaceutics Section, Novartis Institutes for BioMedical Research, East Hanover, New Jersey 07936.
Publications dans "Industrie pharmaceutique" :
2 publications dans cette catégorie
Affiliations :
School of Health Policy and Management, York University, Toronto, ON, Canada.
Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada.
Publications dans "Industrie pharmaceutique" :
2 publications dans cette catégorie
Affiliations :
School of Journalism and Communication, Carleton University, Ottawa, ON, Canada.
Publications dans "Industrie pharmaceutique" :
2 publications dans cette catégorie
Affiliations :
School of Public Policy & Administration, Carleton University, Ottawa, ON, Canada.
Publications dans "Industrie pharmaceutique" :
2 publications dans cette catégorie
Affiliations :
School of Public Policy & Administration, Carleton University, Ottawa, ON, Canada.
Publications dans "Industrie pharmaceutique" :
2 publications dans cette catégorie
Affiliations :
Pharmaceutical Sciences, Pharmaceutical Research and Early Development, Roche Innovation Center, Basel, Switzerland.
Publications dans "Industrie pharmaceutique" :
2 publications dans cette catégorie
Affiliations :
Medicinal Science and Technology, GlaxoSmithKline R&D, Ware, Hertfordshire, UK.
Publications dans "Industrie pharmaceutique" :
2 publications dans cette catégorie
Affiliations :
Pharmaceutical Sciences, Merck & Co., Inc., Kenilworth, New Jersey 07033. Electronic address: filippos_kesisoglou@merck.com.
Publications dans "Industrie pharmaceutique" :
2 publications dans cette catégorie
Affiliations :
Pfizer, Inc, BioTherapeutics PharmSci, 1 Burtt Road, Andover MA 01810, USA.
Publications dans "Industrie pharmaceutique" :
2 publications dans cette catégorie
Affiliations :
Genentech (A Member of the Roche Group), Pharmaceutical Development, 1 DNA Way, South San Francisco, CA 94080, USA.
Publications dans "Industrie pharmaceutique" :
2 publications dans cette catégorie
Affiliations :
Pfizer PGRD, Sandwich CT13 9NJ, UK.
Publications dans "Industrie pharmaceutique" :
2 publications dans cette catégorie
Affiliations :
AstraZeneca UK Limited, Macclesfield SK10 2NA, UK.
Publications dans "Industrie pharmaceutique" :
2 publications dans cette catégorie
Affiliations :
School of Pharmacy and Biomedical Sciences, University of Portsmouth, St. Michael's Building, White Swan Road, Portsmouth PO1 2DT, UK.
Publications dans "Industrie pharmaceutique" :
2 publications dans cette catégorie
Affiliations :
Department of Drug Metabolism and Pharmacokinetics, Genentech, South San Francisco, California, USA.
Publications dans "Industrie pharmaceutique" :
1 publication dans cette catégorie
Affiliations :
Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany.
Publications dans "Industrie pharmaceutique" :
1 publication dans cette catégorie
Affiliations :
Department of Poultry Science, University of Arkansas, Fayetteville, AR, USA.
Publications dans "Industrie pharmaceutique" :
1 publication dans cette catégorie
Affiliations :
Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany. paul.selzer@boehringer-ingelheim.com.
Publications dans "Industrie pharmaceutique" :
Interstitial lung diseases are associated with high morbitity and mortality. Rapid diagnosis in a qualified center is necessary in order to provide the best possible treatment. However, geographic dis...
We conducted a realist review of state-authorized dyslexia pilot projects to understand how they have been implemented and evaluated, and the extent to which they adhere to best practice recommendatio...
Increased noxious noise leads to adverse short-term and long-term effects on the growing neonate. The American Academy of Pediatrics recommends maintaining a noise level of less than 45 decibels (dBA)...
The purpose of this pilot project was to reduce the average noise levels by 39% at the end of an 11-week period....
The location of the project was in a large, high-acuity level IV open-pod layout NICU that consisted of 4 pods, one of which was cardiac-focused. The average baseline noise level in the cardiac pod wa...
At the end of the project, noise levels decreased from 62.6 dBA to 54 dBA, a 13.7% reduction....
At the end of this pilot project it was noted that: Online modules were the best way to educate staff. Parents should be included in the implementation of quality improvement. Healthcare providers nee...
Hospitalized patients after suicide attempts gave informed consent to a postvention project after discharge. A continuous caregiver contacted the subjects monthly by phone for a period of 1 year. In c...
Measuring the hypovolemic resuscitation end point remains a critical care challenge. Our project compared clinical hypovolemia (CH) with three diagnostic adjuncts: 1) noninvasive cardiac output monito...
Adult trauma/surgical intensive care unit patients were prospectively screened for suspected hypovolemia after acute resuscitation, excluding patients with burns, known heart failure, or severe liver/...
44 patients (62% male, median age 60) yielded 65 measures. Positive agreement with CH was 47% for NICOM, 37% for US-IVC and 10% for US-C. None of the three adjuncts correlated with CH (κ -0.045 to 0.0...
None of the adjunct measurements correlated with CH or each other, highlighting that fluid status assessment remains challenging in critical care. US should assess for right ventricular dysfunction pr...
People living with chronic disease should ideally engage with community-based exercise services following hospital-based rehabilitation. However, transition from hospital to community exercise setting...
The aims of this study were to develop and explore the feasibility of a pilot exercise referral pathway between an acute hospital and community gyms for patients with chronic health conditions and to ...
A stakeholder-informed exercise referral pathway was developed and offered to patients following completion of a hospital-based exercise programme for a chronic health condition. The pathway was evalu...
Forty-nine people living with chronic conditions (mean age 72 ± 7.8 years) participated (recruitment rate 59%). The average number of community gym visits over 4 months was 17.4 (range 0-51). Twenty-n...
A structured exercise referral pathway to support exercise transition between hospital and community settings in populations with chronic health conditions appears feasible. Participants reported high...
This manuscript offers findings from a pilot project which prepares nursing students for embodied professional practice through the lens of ethics. Four undergraduate nursing students were mentored by...
Chlamydia disproportionately affects individuals aged 15-24 years. A lack of chlamydia knowledge in this high-risk group likely contributes to decreased testing, but interventions to increase chlamydi...
A pre- and post-test design was used to evaluate participant knowledge of chlamydia before and after completing a nurse-developed web-based education intervention designed for university students....
Forty-seven undergraduate students at one U.S. university participated. A focus group and scientific evidence informed the development of the web-based education....
Participants had a significant increase in chlamydia knowledge after completing the online educational intervention (M = 8.0, SD = 0.000) compared to baseline (M = 6.5, SD = 1.5), t(33) = -5.821, p < ...
In the twenty-first century, health systems have to cope with the challenges posed by their rapidly changing environment. Among these changes, the emergence of digital health solutions is an opportuni...
This study is based on a survey of the dental care provided by three units (Oral Medicine, Periodontology, Orthodontics) of the Department of Community Dentistry, Semmelweis University, Budapest. Duri...
According to our findings, teledentistry has the potential to shorten the visit with an average of 5-10 min per patient, which adds up to 58-116 work hours in a year. If the pilot was rolled out to al...
The rapid development of digital health technologies coupled with the evolving task distribution between health professionals have a great potential to improve health system performance in pursuit of ...
Obesity is a chronic, multifactorial disease which is linked to a number of adverse endocrinological and metabolic conditions. Currently, bariatric surgery is one of the most effective treatments for ...